Amyloid PET scan to measure treatment response in AL cardiac amyloidosis
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with AL cardiac amyloidosis (amyloid proteins in the heart).
- You have already started your first round of treatment, such as anti-plasma cell therapy or targeted therapy.
- You are not pregnant or breastfeeding.
- You do not have severe claustrophobia (fear of enclosed spaces) that would prevent you from having a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study uses two types of imaging (PET/CT and MRI) to see if they can better predict outcomes for people with AL cardiac amyloidosis. The goal is to improve how doctors understand and manage the disease.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study uses special PET and heart MRI scans to better understand light-chain amyloidosis affecting the heart. The scans may help researchers see how the disease behaves in different patient groups and treatment states.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This trial is testing whether a special scan (beta-amyloid PET/CT) can help detect abnormal protein clumps in the brain that are linked to certain diseases, including cancer. The scan might help doctors better understand and track these conditions.
Hear when a new Light Chain Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.